Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

BACKGROUND: Mutations in KRAS result in a constitutively activated MAPK pathway. In KRAS-mutant tumours existing treatment options, e.g. MEK inhibition, have limited efficacy due to resistance through feedback activation of epidermal growth factor receptors (HER). METHODS: In this Phase 1 study, the...

Descripción completa

Detalles Bibliográficos
Autores principales: van Geel, Robin M. J. M., van Brummelen, Emilie M. J., Eskens, Ferry A. L. M., Huijberts, Sanne C. F. A., de Vos, Filip Y. F. L., Lolkema, Martijn P. J. K., Devriese, Lot A., Opdam, Frans L., Marchetti, Serena, Steeghs, Neeltje, Monkhorst, Kim, Thijssen, Bas, Rosing, Hilde, Huitema, Alwin D. R., Beijnen, Jos H., Bernards, René, Schellens, Jan H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156736/
https://www.ncbi.nlm.nih.gov/pubmed/32147669
http://dx.doi.org/10.1038/s41416-020-0776-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156736/
https://www.ncbi.nlm.nih.gov/pubmed/32147669
http://dx.doi.org/10.1038/s41416-020-0776-z

Ejemplares similares